[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin, 2018; 68, 394−424. doi:  10.3322/caac.21492
[2] Zhang M, Tuo JY, Li GC, et al. Cancer incidence and mortality in Hubei cancer registries, 2013. Cancer Res Prev Treat, 2018; 45, 414−9. (In Chinese
[3] Harrison C. Cancer: IL-22: linking inflammation and cancer. Nat Rev Drug Discov, 2013; 12, 504. doi:  10.1038/nrd4058
[4] Wolk K, Witte E, Witte K, et al. Biology of interleukin-22. Semin Immunopathol, 2010; 32, 17−31. doi:  10.1007/s00281-009-0188-x
[5] Wang JD, Li CD, Wan FT, et al. The rs1550117 A>G variant in DNMT3A gene promoter significantly increases non-small cell lung cancer susceptibility in a Han Chinese population. Oncotarget, 2017; 8, 23470−8. doi:  10.18632/oncotarget.15625
[6] Jiang RQ, Tan ZM, Deng L, et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology, 2011; 54, 900−9. doi:  10.1002/hep.24486
[7] Zhang WC, Chen YY, Wei HM, et al. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res, 2008; 14, 6432−9. doi:  10.1158/1078-0432.CCR-07-4401
[8] Liu T, Peng LS, Yu PW, et al. Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer. J Clin Immunol, 2012; 32, 1332−9. doi:  10.1007/s10875-012-9718-8
[9] Welter JF, Gali H, Crish JF, et al. Regulation of human involucrin promoter activity by POU domain proteins. J Biol Chem, 1996; 271, 14727−33. doi:  10.1074/jbc.271.25.14727